je.st
news
Tag: advanced
Goldfaden MD Debuts Doctors Scrub Advanced
2015-08-21 07:00:00| Happi Breaking News
Red tea and seaweed extracts are paired with ruby crystals.
Tags: advanced
doctors
scrub
debuts
Global-Tech Advanced Innovations: An Extraordinary Arbitrage Speculation With 57% Upside To Go
2015-08-19 05:51:36| Appliances - Topix.net
Global-Tech Advanced Innovations, Inc. is a technology company incorporated in the British Virgin Islands in 1991. Its headquarters are in Hong Kong and its manufacturing facilities are in mainland China.
Tags: to
go
advanced
extraordinary
Oilfield Operator Increases Use Of Recycled Produced Water To Nearly 100 Percent With Advanced Filtration
2015-08-19 05:35:01| oilandgasonline News Articles
An oilfield water service provider is helping a Colorado oilfield operator cut water sourcing and hauling costs for hydraulic fracturing by integrating self-cleaningTEQUATIC PLUS F-75 Filters into a water treatment plant, more than tripling the use of recycled produced water for its customer to nearly 100 percent.
Tags: with
advanced
water
produced
Australia to deploy advanced Airbus airport radars at nine airfields
2015-08-19 01:00:00| Airport Technology
Australia will deploy ten advanced airport surveillance radars to enhance security at nine military and civil airfields in the country.
Tags: advanced
australia
airport
deploy
FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, for First-Line Treatment of Advanced Melanoma, and Grants Priority Review
2015-08-18 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Merck Provides Additional Update: FDA Extends Action Date for Additional sBLA in Ipilimumab-Refractory Advanced Melanoma KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy. Merck is seeking approval for KEYTRUDA, at the currently approved dose of 2 mg/kg every three weeks, for the first-line treatment of unresectable or metastatic melanoma patients. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orInvestors:Justin Holko, 908-740-1879An Phan, 908-255-6325 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
review
application
license
Sites : [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] next »